

# Biologia molecular dels tumors del desenvolupament

## Publicacions 2011

Sumatori Factor d'Impacte: 32,734

Acosta S, Mayol G, Rodríguez E, Lavarino C, De Preter K, Kumps C, García I, De Torres C, Mora J. Identification of tumoral glial precursor cells in neuroblastoma. *Cancer Lett* 2011 ; 312 (1) : 73-81 Factor d'impacte: 4,864 Q1

Cardesa T, Colomo L, Gutiérrez G, Chan WC, Weisenburger D, Climent F, González Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel L, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staudt L, Jares P, López Guillermo A, Campo E. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Haematologica* 2011 ; 96 (7) : 996-1001

Conde N, Cruz O, Albert A, Mora J. Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma. *Pediatr Blood Cancer* 2011 ; 57 (6) : 1071-3 Factor d'Impacte: 1,948 Q2

García Armengol R, Guillén A, Costa JM. Meduloblastoma: una presentación infrecuente en la recurrencia local. *Neurocirugia (Astur)* 2011 ; 22 (5) : 453-6 Factor d'impacte: 0,366 Q4

Gutiérrez García E, Cardesa T, Climent F, González Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martínez S, Valera A, Martínez A, Jares P, Pinyol M, García Herrera A, Martínez Trillos A, Giné E, Villamor N, Campo E, Colomo L, López Guillermo A. GELCAB. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Blood* 2011 ; 117 (18) : 4836-43 Factor d'impacte: 10,558 Q1 D1

Gutiérrez García G, García Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G, Martínez Trillos A, Colomo L, Setoain X, Rodríguez S, Giné E, Campo E, López Guillermo A. Comparison of four prognostic scores in peripheral T-cell lymphoma. *Ann Oncol* 2011 ; 22 (2) : 397-404 Factor d'impacte: 6,452 Q1

Mora J. ¿Por qué la quimioterapia no cura a todos los pacientes con cáncer? *An Pediatr Contin* 2011 ; 9 (3) : 191-6

Mora J, De Torres C, Parareda A, Torner F, Galván P, Rodríguez E, Cardesa T, Salvador H, Suñol M, Huguet R, Cruz O. Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents. *Pediatr Blood Cancer* 2011 ; 57 (1) : 69-75 Factor d'impacte: 1,948 Q2

Rives S, Estella J, Gómez P, López Duarte M, De Miguel PG, Verdeguer A, Moreno MJ, Vivanco JL, Couselo JM, Fernández Delgado R, Maldonado M, Tasso M, López Ibor B, Lendínez F, López Almaraz R, Uriz J, Melo M, Fernández Teijeiro A, Rodríguez I, Badell I. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic

leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011 ; 154 (5) : 600-611 Factor d'impacte: 4,942 Q1

Suñol M, Cusí Sanchez V, Cruz O, Kiss R, Lefranc F. Immunohistochemical analyses of  $\alpha$ 1 and  $\alpha$ 3 Na<sup>+</sup>/K<sup>+</sup>-ATPase subunit expression in medulloblastomas. Anticancer Res 2011 ; 31 (3) : 953-8 Factor d'impacte: 1,656 Q3